Ubs Group Ag Alvotech Transaction History

Ubs Group Ag

  • $611 Billion
  • Q3 2025

A detailed history of Ubs Group Ag transactions in Alvotech stock. As of the latest transaction made, Ubs Group Ag holds 26,738 shares of ALVO stock, worth $146,791. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,738
Previous 42,603 37.24%
Holding current value
$146,791
Previous $388,000 43.81%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
SELL
$7.82 - $9.81 $124,064 - $155,635
-15,865 Reduced 37.24%
26,738 $218,000
Q2 2025

Aug 14, 2025
SELL
$7.84 - $11.45 $39,043 - $57,021
-4,980 Reduced 10.47%
42,603 $388,000
Q1 2025

May 13, 2025
SELL
$9.55 - $13.52 $118,907 - $168,337
-12,451 Reduced 20.74%
47,583 $460,000
Q4 2024

Feb 14, 2025
BUY
$11.28 - $13.2 $666,264 - $779,671
59,066 Added 6101.86%
60,034 $792,000
Q3 2024

Nov 14, 2024
BUY
$10.76 - $12.99 $10,394 - $12,548
966 Added 48300.0%
968 $11,000
Q1 2024

May 13, 2024
BUY
$11.36 - $17.27 $22 - $34
2 New
2 $0
Q3 2023

Nov 09, 2023
BUY
$8.12 - $10.07 $633 - $785
78 New
78 $0
Q1 2023

May 12, 2023
SELL
$10.01 - $14.03 $2,992 - $4,194
-299 Reduced 11.58%
2,283 $29,000
Q4 2022

Feb 08, 2023
SELL
$5.76 - $10.05 $46,984 - $81,977
-8,157 Reduced 75.96%
2,582 $25,000
Q3 2022

Nov 10, 2022
SELL
$0.73 - $9.55 $2,122 - $27,761
-2,907 Reduced 21.3%
10,739 $73,000
Q2 2022

Aug 10, 2022
BUY
$8.21 - $11.19 $112,033 - $152,698
13,646 New
13,646 $112,000

Others Institutions Holding ALVO

# of Institutions
65
Shares Held
15M
Call Options Held
0
Put Options Held
0
View Full List

About Alvotech

ALVO Quotes by TradingView
  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $1.37B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email